It is an ingenuous decision made by investors who rushed to consider betrixaban Phase 3 APEX study a failure. Betrixaban is a once-daily orally administered Factor Xa inhibitor anticoagulant.  The Phase 3 AREX study was evaluating the superiority of oral betrixaban’s extended-duration anticoagulation vs. the injectable standard-of-care anticoagulation for the prevention of venous thromboembolism (VTE) in acute medically ill patients.

The 7,513-subject study designed to assess the relative risk of the two therapies consisted of three pre-specified patient groups: Cohort 1 - patients with elevated D-dimer levels (62% of the . . .